Form 8-K - Current report:
SEC Accession No. 0001193125-25-026156
Filing Date
2025-02-13
Accepted
2025-02-13 16:51:54
Documents
15
Period of Report
2025-02-13
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d932957d8k.htm   iXBRL 8-K 38871
2 EX-99.1 d932957dex991.htm EX-99.1 10911
6 GRAPHIC g932957g0214001930710.jpg GRAPHIC 2359
  Complete submission text file 0001193125-25-026156.txt   184163

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nmra-20250213.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nmra-20250213_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nmra-20250213_pre.xml EX-101.PRE 11265
17 EXTRACTED XBRL INSTANCE DOCUMENT d932957d8k_htm.xml XML 3639
Mailing Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472
Business Address 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 (857) 760-0900
Neumora Therapeutics, Inc. (Filer) CIK: 0001885522 (see all company filings)

EIN.: 844367680 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41802 | Film No.: 25621176
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)